EU medtech industry urges caution over pace and type of change
This article was originally published in SRA
Executive Summary
European medical technology association Eucomed feels that the European Commission is not aware of how complex and difficult issues relating to the industry and medical device regulation will get in the next 15 to 20 years. The commission’s approach towards tackling emerging issues – as reflected in its consultation on a potential recast of the medical device directive – suggests that it is moving too fast without all the information it needs, Eucomed believes1,2.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.